Mendus AB Posts 5-Year AML Follow-Up, CML Trial Progress

Mendus presented updated 5-year follow-up from the Phase 2a ADVANCE II AML trial showing durable remissions linked to vididencel-induced immune responses. The company also reported VITAL-CML Phase 1b enrollment at 13/24 with initial data expected in Q4 2026 and topline mid-2027.